Kaken Pharmaceutical and Axcelead DDP Begin Collaboration to Create Innovative New Drugs
Kaken Pharmaceutical Co., Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead...
ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods
Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research...
Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics
We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service...
Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki,...
Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting.
The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to...
Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience
October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as...